Roche’s CEO States that ‘Me-too’ Pharmaceutical Firms will ‘Disappear’

Drug makers who do not offer any genuine value will “disappear” over the next decade, according to Roche’s chief executive, Severin Schwan. Speaking at the Financial Times’ Pharmaceutical and Biotechnology conference in London, Schwan described a three-segment model with highly-innovative companies on one side and generics on the other.  Schwan stated that the number of

Continue Reading

Roche Announces Opening of New R&D Building

Earlier today Roche announced the opening of their new R&D office in Basel, Switzerland. The building, which represents an investment of CHF 250 million, will be used to study and develop pharmaceutical formulations for new active ingredients, as well as produce supplies for global clinical trials. Headquartered in Basel, Roche is a leader in research-focused

Continue Reading

Roche Reports Positive Herceptin Results

Swiss pharmaceutical company, Roche, yesterday announced that the Phase III HannaH study demonstrated comparable efficacy of a new, investigational subcutaneous formulation of Herceptin (trastuzumab) to the standard intravenous infusion of Herceptin in women with HER2-positive early breast cancer. HannaH is a Phase III, open-label study consisting of 596 women with HER2 positive early breast cancer.

Continue Reading

Roche Buy Anadys Pharmaceuticals for $230 Million

Swiss pharmaceutical company, Roche, is to acquire the USA’s Anadys Pharmaceuticals, a hepatitis C specialist, in a cash agreement worth about $230 million. The Swiss company is paying $3.70 per share cash, which represents a 256% premium over Anadys’ closing price of $1.04 on Friday (October 14). The San Diego-based group’s board have agreed to

Continue Reading

Evotec Licenses Alzheimer’s Deal To Roche

Evotec and partner Roche have signed a new agreement to develop a compound with potential in Alzheimer’s disease, replacing an antidepressant programme which was dropped in May. The German biotechnology company said it will receive $10 million in upfront licensing fees as a result of Roche’s decision to collaborate on the development of the new

Continue Reading

Roche’s Tarceva Receives European Approval

Roche announced today that the European Commission has approved Tarceva for use in patients with a genetically distinct type of non-small cell lung cancer in Europe.  This approval will enable the use of Tarceva as a first-line monotherapy in people with locally advanced or metastatic non-small lung cancer with EGFR (epidermal growth factor receptor) activating

Continue Reading

Melanoma Drug Zelboraf Approved by FDA

The US Food and Drug Administration approved Roche’s Zelboraf yesterday for the treatment of patients with advanced melanoma that is beyond the reach of surgery. Zelboraf (vemurafenib) was approved two months ahead of schedule by the FDA and is the second melanoma drug to be approved in 2011 after Bristol-Myers Squibb’s Yervoy (ipilimumab), which debuted

Continue Reading